CFTR and autosomal dominant polycystic kidney disease: Metformin has drawn attention as a potential therapy for ADPKD treatment due to its abilities to activate 5′ AMP-activated protein kinase (AMPK) and suppress cystic fibrosis transmembrane conductance regulator (CFTR) and mTOR [14,15,16,17].